On August 8, 2022, Guangzhou Yinming Biopharmaceutical Technology Co., Ltd. submitted the approval of overseas initial public offering shares (including common shares, preferred shares and other derivative forms of stocks and stocks) to the China Securities Regulatory Commission International Commission, and received the materials on August 8, 2022.

Tianyan survey shows that Yingming Biology is a platform enterprise guided by First-in-Class pharmaceutical innovation. The company has made world-class breakthroughs in the fields of ophthalmic drugs, small molecular immune drugs, new medical and aesthetic drugs and cell therapy. Because there are more than ten kinds of products under research, most of them are competitive breakthrough First-in-Class innovative drugs, and the main products have completed the previous research and development or have been commercialized.

Up to now, Yingming has gone through four rounds of financing, investors include Haisong Capital, Lifeng Capital, Huacheng Venture Capital, Jifeng Capital, Tiger Global Fund, Banyan Capital, Jingcheng Investment, Yatsen, Taixin Capital, Speed of Light China, Huajin Capital, Hengqin Capital, Integrity Venture Capital, Secco Angel Fund, Qianming Capital and so on.